{"success":true,"data":{"pressRelease":{"id":"25596","rtpr_id":"nGNEc0vfTX","ticker":"SILO","exchange":"NASDAQ","all_tickers":["SILO"],"title":"Silo Pharma Files Provisional Patent for Ibogaine-Based Therapeutic Targeting Traumatic Brain Injury ","author":"Globe Newswire","published_at":"2026-05-07T12:05:00.274Z","article_body":"New initiative from Silo Pharma designed to align with federal actions to\naccelerate mental health innovation using psychedelic medicines\n\nSilo Pharma targets unmet need in a drug market with no FDA-approved therapies\nthat address structural or regenerative aspects of traumatic brain injury\n\nTraumatic brain injury therapeutics market estimated to reach $6 billion by\n2032\n\nSARASOTA, FLA., May 07, 2026 (GLOBE NEWSWIRE) -- Silo Pharma (Nasdaq: SILO)\n(“Silo” or “the Company”), a developmental-stage biopharmaceutical\ncompany focused on novel therapeutics and drug delivery systems, today\nannounced a strategic initiative to explore ibogaine-based therapeutics for\nthe treatment of traumatic brain injury (TBI) and associated neuropsychiatric\nconditions.\n\nSilo has filed a provisional patent application with the United States Patent\nand Trademark Office (USPTO) titled “Compositions and Methods for Treating\nTraumatic Brain Injuries and/or Disorders Associated therewith with\nIbogaine.” The invention applies to the use of ibogaine and related\ncompounds for the treatment of TBI, post-traumatic stress disorder (PTSD) and\nassociated conditions.\n\nSilo’s newest drug discovery initiative is in line with recently published\nclinical and neuroimaging findings demonstrating substantial improvements in\npatients with TBI following treatment with ibogaine-based protocols. Reported\noutcomes include significant reductions in depression and anxiety symptoms, as\nwell as measurable structural brain changes, including increased cortical\nthickness, subcortical volume expansion, and reductions in predicted brain age\nfollowing a single treatment.\n\nIn accordance with the Executive Order\n(https://www.globenewswire.com/Tracker?data=L7qEDkqE02-NVYcvXk7pqWjHybIvC2H0lS9LZxJAgQu5ZJdEpim4t4fN6BDSnZg8WUaiiLsCgxiIbDppQbbOLDYhpxnprc8ry55ha-eFdAb3RFp1vPyLZP70LlYpOTD-LP-2gBW1deDvNWSScbTDluRc2IxP0yTr8oEeF6DoUdTjymtcbxXs92C1Jw-1pS1dkk0OjmVIZFON7QzhOFvuc8ZEyexiUF4ZOudW-MOv1lSnLpBAlDgu_DgJ1vXIV0ru7AqEcZ0IXOx7J7OkgjCmjI8EXbtdAkU37LKBum8ZmLuXeek8U9Fw2uh6MscIlvC9Tbain8yuU8epuW8i9zk6Ih6SFx4KWxYxHot235eotKSYM376Y5cJn3tu-eU2l7iU)\nby President Trump announced on April 18, 2026, the FDA has granted\nBreakthrough Therapy designation to specific psychedelic drugs through a\nprogram designed to expedite the development and review of drugs intended to\ntreat serious or life-threatening conditions. The Executive Order cites\nibogaine’s potential for conditions that persist after standard therapies\nare completed.\n\n“Promising clinical findings on ibogaine signify a potential paradigm shift\nin how we think about treating traumatic brain injury and related central\nnervous system (CNS) disorders,” said Eric Weisblum, CEO of Silo Pharma.\n“While many drugs are used off label to manage TBI symptoms like cognitive\ndysfunction or depression, no pharmaceutical agent has ever received FDA\napproval for the direct treatment of TBI. The possibility of not only\naddressing symptoms but also driving measurable structural brain improvements\nopens a compelling new frontier in neurotherapeutics.”\n\nSilo will evaluate the potential of ibogaine and related compounds, including\ndifferentiated protocols and combination approaches, as part of its broader\nstrategy to develop next-generation psychedelics-assisted CNS therapeutics.\nThe Company intends to explore treatment approaches designed to promote\nneuroplasticity, improve functional outcomes, and address the underlying\npathophysiology of TBI.\n\nTBI remains a significant unmet medical need, particularly among military\nveterans and individuals with chronic neuropsychiatric symptoms. No\nFDA-approved treatments address structural or regenerative aspects of\ntraumatic brain injury. Current options are limited to symptomatic support.\n\nThe global traumatic brain injury (TBI) therapeutics market is estimated to\nreach $6.0 billion by 2032, growing at a CAGR of 6.0% between 2025 and\n2032. Key drivers of growth include. The increasing incidence of brain\ninjuries worldwide and rapid advancements in treatment options.(1)\n\n“By expanding into ibogaine-based therapeutics, we are bolstering Silo’s\nposition at the intersection of emerging psychedelic research and\nnext-generation CNS drug development,” Weisblum added. “Silo’s broader\nstrategy focuses on combining novel compounds, innovative delivery systems and\nmeasurable clinical endpoints to drive scalable therapeutic solutions.”\n\nAbout Silo Pharma, Inc.\n\nSilo Pharma is a diversified developmental-stage biopharmaceutical and\ncryptocurrency treasury company. Its therapeutic focus is on addressing\nunderserved conditions, including stress-induced psychiatric disorders,\nchronic pain, and central nervous system (CNS) diseases. The Company’s\nportfolio includes innovative programs such as SPC-15 for PTSD, SP-26 for\nfibromyalgia and chronic pain, and preclinical assets targeting Alzheimer’s\ndisease. Silo’s research is conducted in collaboration with leading\nuniversities and laboratories. silopharma.com\n(https://www.globenewswire.com/Tracker?data=zqDnTpoKA9XTG_Vg2qHLwhpW2U4SGXgh0kTP5Xc0w1bmnxS5MQwsm3PKXCMmXzSr2UpcloXgHpC0lIdZT4LDMeTJms0px8EGuDkoLf_DfjGrss3M6Wy-k-x1q_El4oTWcOaA0Un-qh3yjIY_ZltlnLiiPuRhcX4PaWQphvlhPzur4TXIlUi5c13kAvrwFcSqftsYDvBL-asCgO7IH8mcFK5Prnmm1mS6BcDdcooPzo1pPkBghabMns-hNapWXKRnHvG6i8EVXlw3foG1peXT92R3LnGOQXZzsCrr8nbOekJLHmIoYtHDcleIejYa1H9pLAC_O70UX0erlctQnSRDiM-ydrIhLDzss3j397X2zLlkk02o9EgXRGk5fqzsJl1iw899516WP_0TQQjpsvSltAW31uLhHhuhlZfvMO4WcKC9RxAsLAKdbLE9L_LhdFwXw1DCVykO3aXUTZ5mCSnpeEmCZxgKL5gtS0_ajeGFHrc_tyMYeuzsI2RWnV8pameb_G7cJs1gM68doVh5LepwnReS2hMNQTV1x8MeLDfMXb5jac9yQT-7KdJ4PwAkW_jwumRLS0jYxoVUYnhQ1C8i37lMwyH8xnOJ4-_r9Ijd574O2bMwJLYLfHtvgmJek34f3ELGqRjNhPnwT7HEBRD1F8Cjrxv3UrZGlKPDFa9Eq_nOhxfoRZgibusi6_zCrb9GeuqL3ALjOC8bUtT5Yqss_FIApK3Q1KvjJt5_9pO5k9fVgQ4iR8BWWf0l15kqxgIXSqPqoayf6LksnHQyMwwiv0bM7opNfP5KEcrqV6_TXKAiAaFygnz9Hnki86OQ7CJpvBBGgJp2KCVkFRC8XPil8aF0mJcydGg9tIF973RFbcqOXv5tHqxRQFwAw78omVYy20otJ8dhH7shiqtw1Tr7ze0RSuCU_I51vyKjrCOfbYNF29SbMLieuct-tEAXqnYLaMiSGR9HvCivuJQPzIs1ghFqpKT0BsWnHXr1stWmrd8VrNgPB2qrp-5q9ar5AKscJ-fQL4Uzufk60WQvf9hOkA==)\n\nForward Looking Statements\n\nThis news release contains “forward-looking statements” within the meaning\nof the “safe harbor” provisions of the Private Securities Litigation\nReform Act of 1995. These statements are identified using words “could”,\n“believe”, “anticipate”, “intend”, “estimate”, “expect”,\n“may”, “continue”, “predict”, “potential”, and similar\nexpressions that are intended to identify forward-looking statements. Such\nstatements involve known and unknown risks, uncertainties, and other factors\nthat could cause the actual results of the Company to differ materially from\nthe results expressed or implied by such statements, including statements\nabout the intended use of proceeds from the offering, changes to anticipated\nsources of revenues, future economic and competitive conditions, difficulties\nin developing the Company’s technology platforms, retaining and expanding\nthe Company’s customer base, fluctuations in consumer spending on the\nCompany’s products and other factors. Accordingly, although the Company\nbelieves that the expectations reflected in such forward-looking statements\nare reasonable, there can be no assurance that such expectations will prove to\nbe correct. The Company disclaims any obligations to publicly update or\nrelease any revisions to the forward-looking information contained in this\npress release, whether as a result of new information, future events, or\notherwise, after the date of this press release or to reflect the occurrence\nof unanticipated events except as required by law.\n\nContact\n(800) 705-0120\ninvestors@silopharma.com\n\n(1) Persistence Market Research, August 2025","article_body_html":"","raw_payload":{"data":{"id":"nGNEc0vfTX","title":"Silo Pharma Files Provisional Patent for Ibogaine-Based Therapeutic Targeting Traumatic Brain Injury ","author":"Globe Newswire","ticker":"SILO","created":"2026-05-07T12:05:00.274Z","tickers":["SILO"],"exchange":"NASDAQ","article_body":"New initiative from Silo Pharma designed to align with federal actions to\naccelerate mental health innovation using psychedelic medicines\n\nSilo Pharma targets unmet need in a drug market with no FDA-approved therapies\nthat address structural or regenerative aspects of traumatic brain injury\n\nTraumatic brain injury therapeutics market estimated to reach $6 billion by\n2032\n\nSARASOTA, FLA., May 07, 2026 (GLOBE NEWSWIRE) -- Silo Pharma (Nasdaq: SILO)\n(“Silo” or “the Company”), a developmental-stage biopharmaceutical\ncompany focused on novel therapeutics and drug delivery systems, today\nannounced a strategic initiative to explore ibogaine-based therapeutics for\nthe treatment of traumatic brain injury (TBI) and associated neuropsychiatric\nconditions.\n\nSilo has filed a provisional patent application with the United States Patent\nand Trademark Office (USPTO) titled “Compositions and Methods for Treating\nTraumatic Brain Injuries and/or Disorders Associated therewith with\nIbogaine.” The invention applies to the use of ibogaine and related\ncompounds for the treatment of TBI, post-traumatic stress disorder (PTSD) and\nassociated conditions.\n\nSilo’s newest drug discovery initiative is in line with recently published\nclinical and neuroimaging findings demonstrating substantial improvements in\npatients with TBI following treatment with ibogaine-based protocols. Reported\noutcomes include significant reductions in depression and anxiety symptoms, as\nwell as measurable structural brain changes, including increased cortical\nthickness, subcortical volume expansion, and reductions in predicted brain age\nfollowing a single treatment.\n\nIn accordance with the Executive Order\n(https://www.globenewswire.com/Tracker?data=L7qEDkqE02-NVYcvXk7pqWjHybIvC2H0lS9LZxJAgQu5ZJdEpim4t4fN6BDSnZg8WUaiiLsCgxiIbDppQbbOLDYhpxnprc8ry55ha-eFdAb3RFp1vPyLZP70LlYpOTD-LP-2gBW1deDvNWSScbTDluRc2IxP0yTr8oEeF6DoUdTjymtcbxXs92C1Jw-1pS1dkk0OjmVIZFON7QzhOFvuc8ZEyexiUF4ZOudW-MOv1lSnLpBAlDgu_DgJ1vXIV0ru7AqEcZ0IXOx7J7OkgjCmjI8EXbtdAkU37LKBum8ZmLuXeek8U9Fw2uh6MscIlvC9Tbain8yuU8epuW8i9zk6Ih6SFx4KWxYxHot235eotKSYM376Y5cJn3tu-eU2l7iU)\nby President Trump announced on April 18, 2026, the FDA has granted\nBreakthrough Therapy designation to specific psychedelic drugs through a\nprogram designed to expedite the development and review of drugs intended to\ntreat serious or life-threatening conditions. The Executive Order cites\nibogaine’s potential for conditions that persist after standard therapies\nare completed.\n\n“Promising clinical findings on ibogaine signify a potential paradigm shift\nin how we think about treating traumatic brain injury and related central\nnervous system (CNS) disorders,” said Eric Weisblum, CEO of Silo Pharma.\n“While many drugs are used off label to manage TBI symptoms like cognitive\ndysfunction or depression, no pharmaceutical agent has ever received FDA\napproval for the direct treatment of TBI. The possibility of not only\naddressing symptoms but also driving measurable structural brain improvements\nopens a compelling new frontier in neurotherapeutics.”\n\nSilo will evaluate the potential of ibogaine and related compounds, including\ndifferentiated protocols and combination approaches, as part of its broader\nstrategy to develop next-generation psychedelics-assisted CNS therapeutics.\nThe Company intends to explore treatment approaches designed to promote\nneuroplasticity, improve functional outcomes, and address the underlying\npathophysiology of TBI.\n\nTBI remains a significant unmet medical need, particularly among military\nveterans and individuals with chronic neuropsychiatric symptoms. No\nFDA-approved treatments address structural or regenerative aspects of\ntraumatic brain injury. Current options are limited to symptomatic support.\n\nThe global traumatic brain injury (TBI) therapeutics market is estimated to\nreach $6.0 billion by 2032, growing at a CAGR of 6.0% between 2025 and\n2032. Key drivers of growth include. The increasing incidence of brain\ninjuries worldwide and rapid advancements in treatment options.(1)\n\n“By expanding into ibogaine-based therapeutics, we are bolstering Silo’s\nposition at the intersection of emerging psychedelic research and\nnext-generation CNS drug development,” Weisblum added. “Silo’s broader\nstrategy focuses on combining novel compounds, innovative delivery systems and\nmeasurable clinical endpoints to drive scalable therapeutic solutions.”\n\nAbout Silo Pharma, Inc.\n\nSilo Pharma is a diversified developmental-stage biopharmaceutical and\ncryptocurrency treasury company. Its therapeutic focus is on addressing\nunderserved conditions, including stress-induced psychiatric disorders,\nchronic pain, and central nervous system (CNS) diseases. The Company’s\nportfolio includes innovative programs such as SPC-15 for PTSD, SP-26 for\nfibromyalgia and chronic pain, and preclinical assets targeting Alzheimer’s\ndisease. Silo’s research is conducted in collaboration with leading\nuniversities and laboratories. silopharma.com\n(https://www.globenewswire.com/Tracker?data=zqDnTpoKA9XTG_Vg2qHLwhpW2U4SGXgh0kTP5Xc0w1bmnxS5MQwsm3PKXCMmXzSr2UpcloXgHpC0lIdZT4LDMeTJms0px8EGuDkoLf_DfjGrss3M6Wy-k-x1q_El4oTWcOaA0Un-qh3yjIY_ZltlnLiiPuRhcX4PaWQphvlhPzur4TXIlUi5c13kAvrwFcSqftsYDvBL-asCgO7IH8mcFK5Prnmm1mS6BcDdcooPzo1pPkBghabMns-hNapWXKRnHvG6i8EVXlw3foG1peXT92R3LnGOQXZzsCrr8nbOekJLHmIoYtHDcleIejYa1H9pLAC_O70UX0erlctQnSRDiM-ydrIhLDzss3j397X2zLlkk02o9EgXRGk5fqzsJl1iw899516WP_0TQQjpsvSltAW31uLhHhuhlZfvMO4WcKC9RxAsLAKdbLE9L_LhdFwXw1DCVykO3aXUTZ5mCSnpeEmCZxgKL5gtS0_ajeGFHrc_tyMYeuzsI2RWnV8pameb_G7cJs1gM68doVh5LepwnReS2hMNQTV1x8MeLDfMXb5jac9yQT-7KdJ4PwAkW_jwumRLS0jYxoVUYnhQ1C8i37lMwyH8xnOJ4-_r9Ijd574O2bMwJLYLfHtvgmJek34f3ELGqRjNhPnwT7HEBRD1F8Cjrxv3UrZGlKPDFa9Eq_nOhxfoRZgibusi6_zCrb9GeuqL3ALjOC8bUtT5Yqss_FIApK3Q1KvjJt5_9pO5k9fVgQ4iR8BWWf0l15kqxgIXSqPqoayf6LksnHQyMwwiv0bM7opNfP5KEcrqV6_TXKAiAaFygnz9Hnki86OQ7CJpvBBGgJp2KCVkFRC8XPil8aF0mJcydGg9tIF973RFbcqOXv5tHqxRQFwAw78omVYy20otJ8dhH7shiqtw1Tr7ze0RSuCU_I51vyKjrCOfbYNF29SbMLieuct-tEAXqnYLaMiSGR9HvCivuJQPzIs1ghFqpKT0BsWnHXr1stWmrd8VrNgPB2qrp-5q9ar5AKscJ-fQL4Uzufk60WQvf9hOkA==)\n\nForward Looking Statements\n\nThis news release contains “forward-looking statements” within the meaning\nof the “safe harbor” provisions of the Private Securities Litigation\nReform Act of 1995. These statements are identified using words “could”,\n“believe”, “anticipate”, “intend”, “estimate”, “expect”,\n“may”, “continue”, “predict”, “potential”, and similar\nexpressions that are intended to identify forward-looking statements. Such\nstatements involve known and unknown risks, uncertainties, and other factors\nthat could cause the actual results of the Company to differ materially from\nthe results expressed or implied by such statements, including statements\nabout the intended use of proceeds from the offering, changes to anticipated\nsources of revenues, future economic and competitive conditions, difficulties\nin developing the Company’s technology platforms, retaining and expanding\nthe Company’s customer base, fluctuations in consumer spending on the\nCompany’s products and other factors. Accordingly, although the Company\nbelieves that the expectations reflected in such forward-looking statements\nare reasonable, there can be no assurance that such expectations will prove to\nbe correct. The Company disclaims any obligations to publicly update or\nrelease any revisions to the forward-looking information contained in this\npress release, whether as a result of new information, future events, or\notherwise, after the date of this press release or to reflect the occurrence\nof unanticipated events except as required by law.\n\nContact\n(800) 705-0120\ninvestors@silopharma.com\n\n(1) Persistence Market Research, August 2025"},"type":"article","timestamp":"2026-05-07T12:05:00.362948098Z","server_sent_at_ms":1778155500362},"received_at":"2026-05-07T12:05:00.523Z","source_url":"https://www.globenewswire.com/news-release/2026/05/07/3289971/0/en/silo-pharma-files-provisional-patent-for-ibogaine-based-therapeutic-targeting-traumatic-brain-injury.html"},"analysis":{"id":"20045","press_release_id":"25596","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"operations_update","narrative":"Silo Pharma filed a provisional patent application for ibogaine-based therapeutics targeting traumatic brain injury (TBI) and associated neuropsychiatric conditions.\n\nThe initiative aligns with a recent federal Executive Order to accelerate psychedelic medicine innovation, targeting a market estimated to reach $6 billion by 2032.\n\nCEO Eric Weisblum noted that no current FDA-approved therapies address the structural aspects of TBI, positioning this approach as a potential paradigm shift in neurotherapeutics.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Early-stage pipeline expansion into ibogaine for TBI, riding regulatory tailwinds."},"keyFigures":{"customDimensions":{"tbi_cAGR_2025_2032":"6.0%","tbi_market_size_2032":"$6.0 billion"}},"quotedText":"Promising clinical findings on ibogaine signify a potential paradigm shift in how we think about treating traumatic brain injury and related central nervous system (CNS) disorders","namedEntities":{"people":[{"name":"Eric Weisblum","role":"CEO"}],"products":["SPC-15","SP-26","Ibogaine"],"companies":[{"name":"Silo Pharma","ticker":"SILO"},{"name":"Persistence Market Research","relationship":"data source"}],"dollarAmounts":[{"amount":"$6 billion","context":"estimated global traumatic brain injury therapeutics market by 2032"}]},"materialImpact":{"score":2,"reasoning":"Provisional patent filing for an early-stage drug discovery initiative targeting TBI. While the strategy aligns with favorable regulatory tailwinds and a large addressable market, the project is in the discovery phase with no clinical data or revenue yet."},"tickerRelevance":{"others":[],"primary":"SILO"},"globalImportance":10,"audienceRelevance":15,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"micro-cap","eventGravity":"patent-filing","sectorWeight":"biotech","issuerAuthored":true}},"event_type":"operations_update","event_type_secondary":null,"sentiment":"bullish","material_impact_score":2,"narrative":"Silo Pharma filed a provisional patent application for ibogaine-based therapeutics targeting traumatic brain injury (TBI) and associated neuropsychiatric conditions.\n\nThe initiative aligns with a recent federal Executive Order to accelerate psychedelic medicine innovation, targeting a market estimated to reach $6 billion by 2032.\n\nCEO Eric Weisblum noted that no current FDA-approved therapies address the structural aspects of TBI, positioning this approach as a potential paradigm shift in neurotherapeutics.","key_figures":{"customDimensions":{"tbi_cAGR_2025_2032":"6.0%","tbi_market_size_2032":"$6.0 billion"}},"named_entities":{"people":[{"name":"Eric Weisblum","role":"CEO"}],"products":["SPC-15","SP-26","Ibogaine"],"companies":[{"name":"Silo Pharma","ticker":"SILO"},{"name":"Persistence Market Research","relationship":"data source"}],"dollarAmounts":[{"amount":"$6 billion","context":"estimated global traumatic brain injury therapeutics market by 2032"}]},"model_name":"glm-4.7","prompt_hash":"sha256:f66160e0fe5301b2","schema_hash":"sha256:12363694422af5d9","created_at":"2026-05-07T22:11:26.575Z","global_importance":10,"audience_relevance":15,"importance_components":{"tickerTier":"micro-cap","eventGravity":"patent-filing","sectorWeight":"biotech","issuerAuthored":true}},"durationMs":86009,"modelName":"glm-4.7"}}